We also provided the evidence that pre-treatment with PTC-209, a BMI1 inhibitor, could sensitize NSCLC tumors derived from pemetrexed-resistant cells to pemetrexed treatment. This evidence concerns the gene BMI1 and non-small cell lung carcinoma.